About CStone PharmaceuticalsCStone Pharmaceuticals Co., Ltd. engages in the research and development of immuno-based combination therapeutics for oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases. The company is based in China.
CEO: Frank Jiang, MD, PhD
95 articles with CStone Pharmaceuticals
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
CStone Pharmaceuticals, announced the presentation of the final progression-free survival analysis results from the registrational GEMSTONE-301 study of sugemalimab as a consolidation therapy in patients with unresectable stage III non-small cell lung cancer whose disease had not progressed after concurrent or sequential chemoradiotherapy at the IASLC 2022 World Conference on Lung Cancer.
Unnamed sources “familiar with the matter” informed Bloomberg that CStone's leadership team is working with Goldman Sachs to determine if there are interested buyers.
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
CStone Pharmaceuticals and Pfizer Inc. announced that the National Medical Products Administration of China has approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the first patient has been enrolled in the U.S. in the Phase 1 clinical trial for CS5001.
Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.
1/24/2022Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
CStone Pharmaceuticals, a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced that the GEMSTONE-302 registrational clinical study of sugemalimab for the first-line treatment of metastatic non-small cell lung cancer met the overall survival endpoint.
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration
CStone Pharmaceuticals announced that the investigational new drug application of CS5001, a potential global best-in-class antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 has received a STUDY MAY PROCEED letter from the U.S. Food and Drug Administration.
Today, the FDA approved two new drug applications. One is for Spero's tebipenem HBr oral tablets and the second is CStone's IND application for CS5001.
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly ® ) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy.
CStone announced New Drug Approval of Cejemly® (Sugemalimab) in China to Potentially Reshape The Landscape of Immuno-oncology Therapy in Lung Cancer
CStone Pharmaceuticals is pleased to announce that the National Medical Products Administration of China has approved the new drug application of anti-PD-L1 monoclonal antibody Cejemly® in combination with chemotherapy for treatment-naïve metastatic non-small cell lung cancer patients.
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region.
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
Sugemalimab is the first PD(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III non-small cell lung cancer (NSCLC) patients after treatment with either concurrent or sequential chemoradiotherapy
CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today a licensing agreement with LegoChem Biosciences, Inc. ("LCB", KOSDAQ:141080), for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC").
CStone Pharmaceuticals announced the completion of the Share Subscription Agreement through which an affiliate of Pfizer Inc. subscribed for newly issued CStone shares at approximately US$200 million, bringing into effect the multifaceted strategic collaboration that the companies announced on September 30, 2020.
Pfizer to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.